Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Althaea Officinalis→

Althaea Officinalis Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
90063-41-5
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical herbal drugmarshmallow root mucilage and demulcent
Mechanism of action
Mucilage polysaccharides form a soothing protective film on oral and pharyngeal mucosa. The effect is primarily local and demulcent rather than receptor-mediated.
Indications / reported uses
  • Traditional herbal use for symptomatic relief of oral or pharyngeal irritation and associated dry cough in adults and children above the age specified by the product monograph; use is preparation-specific

Sources: EMA herbal monograph — Althaea officinalis radix · EMA herbal medicinal products — Marshmallow root · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Althaea Officinalis Environmental Risk Assessment (ERA) (the Althaea Officinalis ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.